We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+7.34%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$7.05B
AUM Growth
+$688M
(+11%)
Cap. Flow
+$306M
Cap. Flow
% of AUM
4.35%
Top 10 Holdings %
Top 10 Hldgs %
15.99%
Holding
1,149
New
136
Increased
453
Reduced
359
Closed
174
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$40.4M |
| 2 |
Amazon
AMZN
|
+$35M |
| 3 |
TJX Companies
TJX
|
+$34.6M |
| 4 |
Phillips 66
PSX
|
+$33.1M |
| 5 |
Mastercard
MA
|
+$32.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$31.7M |
| 2 |
Cigna
CI
|
+$27.3M |
| 3 |
Meta Platforms (Facebook)
META
|
+$21.6M |
| 4 |
JPMorgan Chase
JPM
|
+$21M |
| 5 |
Marvell Technology
MRVL
|
+$20.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.29% |
| 2 | Financials | 17.18% |
| 3 | Consumer Discretionary | 12.24% |
| 4 | Industrials | 11.66% |
| 5 | Healthcare | 10.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VVUS
926
DELISTED
Vivus Inc
VVUS
| $201K | ﹤0.01% |
45,469
+32,744
| +257% | +$205K |
|
927
Ribbon Communications
RBBN
$354M
| $199K | ﹤0.01% |
+29,099
| New | +$207K |
|
|
EXPR
928
DELISTED
Express, Inc.
EXPR
| $197K | ﹤0.01% |
890
-15,331
| -95% | -$3.13M |
|
929
Geospace Technologies
GEOS
$91.6M
| $194K | ﹤0.01% |
14,165
| – | – |
|
930
Shore Bancshares
SHBI
$790M
| $194K | ﹤0.01% |
+10,886
| New | +$205K |
|
|
INWK
931
DELISTED
InnerWorkings, Inc.
INWK
| $194K | ﹤0.01% |
24,535
-177,688
| -88% | -$1.39M |
|
932
Lifecore Biomedical
LFCR
$162M
| $193K | ﹤0.01% |
+13,400
| New | +$185K |
|
933
Ovid Therapeutics
OVID
$435M
| $193K | ﹤0.01% |
+34,110
| New | +$259K |
|
934
Aviat Networks
AVNW
$262M
| $189K | ﹤0.01% |
23,392
-3,422
| -13% | -$28.1K |
|
935
Element Solutions
ESI
$9.12B
| $188K | ﹤0.01% |
15,100
-143,790
| -90% | -$1.8M |
|
936
Zevra Therapeutics
ZVRA
$563M
| $181K | ﹤0.01% |
2,359
-725
| -24% | -$56.6K |
|
|
PMBC
937
DELISTED
Pacific Mercantile Bancorp
PMBC
| $181K | ﹤0.01% |
19,370
+6,571
| +51% | +$64.8K |
|
|
OMED
938
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $180K | ﹤0.01% |
84,730
+208
| +0.2% | +$498 |
|
939
Spero Therapeutics
SPRO
$68.9M
| $174K | ﹤0.01% |
16,523
-17,155
| -51% | -$199K |
|
|
DERM
940
DELISTED
Dermira, Inc.
DERM
| $172K | ﹤0.01% |
+15,800
| New | +$159K |
|
|
SYNC
941
DELISTED
Synacor, Inc.
SYNC
| $171K | ﹤0.01% |
106,882
+20,827
| +24% | +$41.7K |
|
942
ImmunityBio
IBRX
$7.44B
| $170K | ﹤0.01% |
46,047
-48,123
| -51% | -$152K |
|
|
AQ
943
DELISTED
Aquantia Corp. Common Stock
AQ
| $167K | ﹤0.01% |
+13,090
| New | +$165K |
|
944
Nature's Sunshine
NATR
$359M
| $162K | ﹤0.01% |
18,500
+2,300
| +14% | +$20.3K |
|
|
ICAD
945
DELISTED
iCAD Inc
ICAD
| $161K | ﹤0.01% |
55,414
| – | – |
|
|
EGIO
946
DELISTED
Edgio, Inc. Common Stock
EGIO
| $156K | ﹤0.01% |
776
| – | – |
|
947
SandRidge Energy
SD
$510M
| $154K | ﹤0.01% |
14,200
| – | – |
|
|
CSLT
948
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $150K | ﹤0.01% |
55,710
-39,548
| -42% | -$140K |
|
949
Key Tronic
KTCC
$40.3M
| $149K | ﹤0.01% |
19,433
-1,455
| -7% | -$11.3K |
|
|
UCTT
950
Ultra Clean Holdings
UCTT
$4.16B
| $149K | ﹤0.01% |
11,870
| – | – |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2018 Portfolio in Review
As of Q3 2018, Jacobs Levy Equity Management held 1,149 positions worth $7.05B, up 11% from $6.36B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Jacobs Levy Equity Management deployed $306M of net new capital in Q3 2018, opening 136 new positions and adding to 453 existing holdings. Its largest new stake was TJX Companies: 673,440 shares worth $37.7M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Eli Lilly, an estimated $31.7M trimmed.
- Jacobs Levy Equity Management's largest Q3 2018 buy was TJX Companies: 673,440 shares worth $37.7M.
- Jacobs Levy Equity Management added most to Alphabet (Google) Class C in Q3 2018, an estimated $40.4M increase.
- Jacobs Levy Equity Management's biggest Q3 2018 reduction was Eli Lilly, cutting an estimated $31.7M.
- Jacobs Levy Equity Management fully exited Dun & Bradstreet in Q3 2018, selling an estimated $17.2M.
- Jacobs Levy Equity Management's ten largest holdings make up 16% of its $7.05B portfolio in Q3 2018.
- Jacobs Levy Equity Management opened 136 new positions and closed 174 in Q3 2018.
- Jacobs Levy Equity Management's portfolio value rose 11% quarter-over-quarter to $7.05B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.